Stock Events

Stock Events

Strategic Partners A/S 

€82
0
+€1+1.23% Monday 17:16

Statistics

Day High
82
Day Low
82
52W High
156
52W Low
72
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25AprExpected
Q1 2023
-540.99
-540.65
-540.32
-539.99
Expected EPS
-540.9877223862783
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1TB0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap28.56B
Biogen is a biotech firm with a strong focus on neurodegenerative diseases, similar to Orphazyme's focus on rare diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.09B
Vertex Pharmaceuticals is involved in treating cystic fibrosis, a rare disease, showing its capability and interest in the rare disease market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.39B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, aligning with Orphazyme's rare disease treatment goals.
Sarepta Therapeutics
SRPT
Mkt Cap2.11B
Sarepta Therapeutics specializes in the treatment of rare genetic diseases, particularly in the area of Duchenne muscular dystrophy.
Ionis Pharmaceuticals
IONS
Mkt Cap12.51B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, working on treatments for rare diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the same rare disease space as Orphazyme.
CRISPR Therapeutics
CRSP
Mkt Cap5.29B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat the genetic roots of many rare diseases.
Novo Nordisk
NVO
Mkt Cap204.22B
Novo Nordisk, while known for diabetes care, is expanding into treatments for rare blood disorders, showing its growing interest in the rare disease sector.
Pfizer
PFE
Mkt Cap146.36B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the rare disease market space.

About

Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. Strategic Partners A/S was incorporated in 2009 and is based in Herlev, Denmark.
Show more...
CEO
Mr. Jakob Færch Bendtsen
Employees
1
Country
Denmark
ISIN
DK0062502894

Listings

CO
DK
STRAP.CO
STU
DE
1TB0.STU
F
DE
1TB0.F
MU
DE
1TB0.MU

0 Comments

Share your thoughts

FAQ

What is Strategic Partners A/S stock price today?▼
The current price of 1TB0.STU is €82 EUR — it has increased by +1.23% in the past 24 hours. Watch Strategic Partners A/S stock price performance more closely on the chart.
What is Strategic Partners A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Strategic Partners A/S stocks are traded under the ticker 1TB0.STU.
Is Strategic Partners A/S stock price growing?▼
1TB0.STU stock has risen by +1.23% compared to the previous week, the month change is a +1.23% rise, over the last year Strategic Partners A/S has showed a -34.4% decrease.
When is the next Strategic Partners A/S earnings date?▼
Strategic Partners A/S is going to release the next earnings report on September 15, 2026.
How many employees does Strategic Partners A/S have?▼
As of May 12, 2026, the company has 1 employees.
In which sector is Strategic Partners A/S located?▼
Strategic Partners A/S operates in the Other sector.
When did Strategic Partners A/S complete a stock split?▼
Strategic Partners A/S has not had any recent stock splits.
Where is Strategic Partners A/S headquartered?▼
Strategic Partners A/S is headquartered in Herlev, Denmark.